Hype drives biotech stocks in early stages whereas now it is up to Elite to put up or shut up and prove results. Future pipeline is heavily discounted in DCF analyses as there are required studies and time doesn't work in our favor. $10 is an unrealistic dream.
News 
Market Data 
Discover 
